NCT06978920View on ClinicalTrials.gov

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

December 1, 2028

Conditions
Parkinson Disease
Interventions
DRUG

Allogeneic dopaminergic neural precursor cell(NCR201)

Bilateral implantation

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of USTC, Hefei

Sponsors
All Listed Sponsors
lead

Nuwacell Biotechnologies Co., Ltd.

INDUSTRY

NCT06978920 - A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease | Biotech Hunter | Biotech Hunter